Literature DB >> 17609405

Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism.

D Vezzosi1, A Bennet, J Fauvel, P Caron.   

Abstract

OBJECTIVE: We evaluated the respective value of insulin, C-peptide and proinsulin levels in 33 patients with endogenous hyperinsulinism and in 67 controls to determine the best parameters and thresholds to make or to rule out the diagnosis of endogenous hyperinsulinism.
RESULTS: When blood glucose levels were below 2.5 mmol/l, insulin was <21 pmol/l in 8-35% of the patients and in all controls; C-peptide was >0.2 nmol/l in all insulinomas but not in the nesidioblastosis or in the controls; proinsulin was >5 pmol/l in all patients but not in the controls. When fasting blood glucose levels reached 2.5-3.3 mmol/l, proinsulin was <22 pmol/l in all the controls and >22 pmol/l in 74% of the patients. Proinsulin after an overnight fast was below 22 pmol/l in all non-obese controls and above 22 pmol/l in 73% of non-obese patients.
CONCLUSION: Proinsulin levels above 5 pmol/l with blood glucose levels below 2.5 mmol/l during a 72 h fast test represent the best criterion for the diagnosis of endogenous hyperinsulinism, reaching 100% diagnostic specificity and sensitivity. Concomitant C-peptide levels above 0.2 nmol/l also make the diagnosis of all our insulinoma patients, not the diagnosis of nesidioblastosis, while insulin levels have much less diagnostic accuracy. Whether proinsulin levels above 22 pmol/l could also make the diagnosis of endogenous hyperinsulinism in part of the patients at the time of fasting blood glucose levels between 2.5 and 3.3 mmol/l or after an overnight fast in non-obese subjects needs further study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609405     DOI: 10.1530/EJE-07-0109

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  28 in total

1.  Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.

Authors:  Frank Musshoff; Cornelius Hess; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-10-07       Impact factor: 2.686

Review 2.  Diagnosis and management of insulinoma.

Authors:  Takehiro Okabayashi; Yasuo Shima; Tatsuaki Sumiyoshi; Akihito Kozuki; Satoshi Ito; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 3.  Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

Authors:  Christian Fottner; Martina Ferrata; Matthias M Weber
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

4.  Spontaneous hypoglycemia: diagnostic evaluation and management.

Authors:  Leelavathy Kandaswamy; Rajeev Raghavan; Joseph M Pappachan
Journal:  Endocrine       Date:  2016-03-07       Impact factor: 3.633

Review 5.  Occult sporadic insulinoma: localization and surgical strategy.

Authors:  Bassam Abboud; Joe Boujaoude
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

Review 6.  Growth factor control of pancreatic islet regeneration and function.

Authors:  Anke Assmann; Charlotte Hinault; Rohit N Kulkarni
Journal:  Pediatr Diabetes       Date:  2008-09-19       Impact factor: 4.866

7.  PROPOSAL OF A REVISIONAL SURGERY TO TREAT NON-INSULINOMA HYPERINSULINEMIC HYPOGLICEMIA POSTGASTRIC BYPASS.

Authors:  José Sampaio-Neto; Alcides José Branco-Filho; Luis Sérgio Nassif; André Thá Nassif; Flávia David João De Masi; Daniele Rezende Ximenez
Journal:  Arq Bras Cir Dig       Date:  2015 Nov-Dec

Review 8.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

9.  Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas.

Authors:  M Toaiari; M V Davì; L Dalle Carbonare; L Boninsegna; C Castellani; M Falconi; G Francia
Journal:  J Endocrinol Invest       Date:  2013-04-18       Impact factor: 4.256

10.  Diagnosis of insulinoma in a patient with hypoglycemia without obvious hyperinsulinemia.

Authors:  Catarina Coelho; Maralyn R Druce; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.